Cu(II) promotes amyloid pore formation

Biochemical and Biophysical Research Communications

Volumn 464, Issue 1, 2015, Pages 342-347

  Zhang, Hangyu ^a,d   Rochet, Jean Christophe ^b   Stanciu, Lia A ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d University of Washington   (United States)

Author keywords

Amyloid; Heavy metal; Parkinson's disease; Protofibril; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; BAICALEIN; CUPRIC ION; COPPER; DIVALENT CATION; FLAVANONE DERIVATIVE; PROTEIN AGGREGATE; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE; THIOFLAVINE;

ANIMAL CELL; ARTICLE; BETA SHEET; CHANNEL GATING; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; KINETICS; OXIDATION REDUCTION REACTION; PROTEIN SECONDARY STRUCTURE; SPECTROFLUOROMETRY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; AMYLOID; CATIONS, DIVALENT; COPPER; FLAVANONES; HUMANS; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; OXIDATION-REDUCTION; PROTEIN AGGREGATES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; THIAZOLES;

EID: 84937637686     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.06.156     Document Type: Article

References (42)

1. A.L. Fink The aggregation and fibrillation of alpha-synuclein Acc. Chem. Res. 39 2006 628 634
2. D.R. Brown Oligomeric alpha-synuclein and its role in neuronal death IUBMB Life 62 2010 334 339
3. C.A. Lasagna-Reeves, C.G. Glabe, and R. Kayed Amyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain J. Biol. Chem. 286 2011 22122 22130
4. H. Jang, F.T. Arce, S. Ramachandran, R. Capone, R. Azimova, B.L. Kagan, R. Nussinov, and R. Lal Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and down syndrome Proc. Natl. Acad. Sci. 107 2010 6538 6543
5. R. Kayed, A. Pensalfini, L. Margol, Y. Sokolov, F. Sarsoza, E. Head, J. Hall, and C. Glabe Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer J. Biol. Chem. 284 2009 4230 4237
6. F. Schmidt, J. Levin, F. Kamp, H. Kretzschmar, A. Giese, and K. Bötzel Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-Synuclein oligomers in lipid membranes PLoS One 7 2012 e42545
7. H.-Y. Kim, M.-K. Cho, A. Kumar, E. Maier, C. Siebenhaar, S. Becker, C.O. Fernandez, H.A. Lashuel, R. Benz, A. Lange, and M. Zweckstetter Structural properties of pore-forming oligomers of α-Synuclein J. Am. Chem. Soc. 131 2009 17482 17489
8. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz, and P.T. Lansbury Neurodegenerative disease - amyloid pores from pathogenic mutations Nature 418 2002 291-291
9. T.T. Ding, S.J. Lee, J.C. Rochet, and P.T. Lansbury Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes Biochemistry 41 2002 10209 10217
10. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, J.C. Kessler, and P.T. Lansbury Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
11. B.D. van Rooijen, M.M.A.E. Claessens, and V. Subramaniam Membrane permeabilization by oligomeric alpha-Synuclein: in search of the mechanism PLoS One 5 2010
12. H.A. Lashuel, and P.T. Lansbury Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39 2006 167 201
13. A. Quist, L. Doudevski, H. Lin, R. Azimova, D. Ng, B. Frangione, B. Kagan, J. Ghiso, and R. Lal Amyloid ion channels: a common structural link for protein-misfolding disease Proc. Natl. Acad. Sci. U. S. A. 102 2005 10427 10432
14. H. Zhang, A. Griggs, J.-C. Rochet, and Lia A. Stanciu In vitro study of α-Synuclein protofibrils by Cryo-EM suggests a Cu2+-dependent aggregation pathway Biophys. J. 104 2013 2706 2713
15. A.L. Feldman, A.L.V. Johansson, G. Nise, M. Gatz, N.L. Pedersen, and K. Wirdefeldt Occupational exposure in Parkinsonian disorders: A 43-year prospective cohort study in men Park. Relat. Disord. 17 2011 677 682
16. K.J. Barnham, and A.I. Bush Metals in Alzheimer's and Parkinson's diseases Curr. Opin. Chem. Biol. 12 2008 222 228
17. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko Metals, oxidative stress and neurodegenerative disorders Mol. Cell. Biochem. 345 2010 91 104
18. K. Jomova, and M. Valko Advances in metal-induced oxidative stress and human disease Toxicology 283 2011 65 87
19. S.J. Chinta, and J.K. Andersen Redox imbalance in Parkinson's disease Biochimica Biophysica Acta (BBA) - General Subj. 1780 2008 1362 1367
20. M. Bisaglia, I. Tessari, S. Mammi, and L. Bubacco Interaction between α-Synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease NeuroMolecular Med. 11 2009 239 251
21. V.N. Uversky, J. Li, and A.L. Fink Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein: a possible molecular link between Parkinson's disease and heavy metal exposure J. Biol. Chem. 276 2001 44284 44296
22. R.M. Rasia, C.W. Bertoncini, D. Marsh, W. Hoyer, D. Cherny, M. Zweckstetter, C. Griesinger, T.M. Jovin, and C.O. Fernández Structural characterization of copper(II) binding to α-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 102 2005 4294 4299
23. C.G. Dudzik, E.D. Walter, and G.L. Millhauser Coordination features and affinity of the Cu2+ site in the α-Synuclein protein of Parkinson's disease Biochemistry 50 2011 1771 1777
24. A. Binolfi, A.A. Valiente-Gabioud, R. Duran, M. Zweckstetter, C. Griesinger, and C.O. Fernandez Exploring the structural details of Cu(I) binding to α-Synuclein by NMR spectroscopy J. Am. Chem. Soc. 133 2010 194 196
25. B. Cheng, H. Gong, H.W. Xiao, R.B. Petersen, L. Zheng, and K. Huang Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases Biochim. Biophys. Acta-General Subj. 1830 2013 4860 4871
26. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. Engemann, A. Pastore, and E.E. Wanker EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15 2008 558 566
27. S. Tian, G.R. He, J.K. Song, S.B. Wang, W.Y. Xin, D. Zhang, and G.H. Du Pharmacokinetic study of baicalein after oral administration in monkeys Fitoterapia 83 2012 532 540
28. M.L. Jiang, Y. Porat-Shliom, Z. Pei, Y. Cheng, L. Xiang, K. Sommers, Q. Li, F. Gillardon, B. Hengerer, C. Berlinicke, W.W. Smith, D.J. Zack, M.A. Poirier, C.A. Ross, and W.Z. Duan Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism J. Neurochem. 114 2010 419 429
29. D.P. Hong, A.L. Fink, and V.N. Uversky Structural characteristics of alpha-Synuclein oligomers stabilized by the flavonoid baicalein J. Mol. Biol. 383 2008 214 223
30. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of α-Synuclein and disaggregates existing fibrils J. Biol. Chem. 279 2004 26846 26857
31. J.H. Lu, M.T. Ardah, S.S.K. Durairajan, L.F. Liu, L.X. Xie, W.F.D. Fong, M.Y. Hasan, J.D. Huang, O.M.A. El-Agnaf, and M. Li Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents A beta peptide fibrillation and oligomerisation Chembiochem 12 2011 615 624
32. D.-P. Hong, A.L. Fink, and V.N. Uversky Structural characteristics of α-Synuclein oligomers stabilized by the flavonoid baicalein J. Mol. Biol. 383 2008 214 223
33. J. Kong, and S. Yu Fourier transform infrared spectroscopic analysis of protein secondary structures Acta Biochim. Biophys. Sinica 39 2007 549 559
34. A. Anandhan, H. Rodriguez-Rocha, I. Bohovych, A.M. Griggs, L. Zavala-Flores, E.M. Reyes-Reyes, J. Seravalli, L.A. Stanciu, J. Lee, J.-C. Rochet, O. Khalimonchuk, and R. Franco Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways Neurobiol. Dis. 2014 10.1016/j.nbd.2014.11.018 (in press)
35. J.A. Wright, X.Y. Wang, and D.R. Brown Unique copper-induced oligomers mediate alpha-synuclein toxicity FASEB J. 23 2009 2384 2393
36. N.B. Cole, D.D. Murphy, J. Lebowitz, L. Di Noto, R.L. Levine, and R.L. Nussbaum Metal-catalyzed oxidation of α-Synuclein J. Biol. Chem. 280 2005 9678 9690
37. J.T. Pedersen, J. Ostergaard, N. Rozlosnik, B. Gammelgaard, and N.H.H. Heegaard Cu(II) mediates kinetically distinct, Non-amyloidogenic aggregation of amyloid-beta peptides J. Biol. Chem. 286 2011 26952 26963
38. D.R. Brown Metal binding to alpha-synuclein peptides and its contribution to toxicity Biochem. Biophys. Res. Commun. 380 2009 377 381
39. S.R. Paik, H.J. Shin, J.H. Lee, C.S. Chang, and J. Kim Copper(II)-induced self-oligomerization of alpha-synuclein Biochem. J. 340 1999 821 828
40. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, R.E. Williamson, and P.T. Lansbury Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc. Natl. Acad. Sci. U. S. A. 97 2000 571 576
41. H.A. Lashuel, B.M. Petre, J. Wall, M. Simon, R.J. Nowak, T. Walz, and P.T. Lansbury alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils J. Mol. Biol. 322 2002 1089 1102
42. X. Mu, G. He, Y. Cheng, X. Li, B. Xu, and G. Du Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro Pharmacol. Biochem. Behav. 92 2009 642 648